stockrowRevolution Medicines, Inc.
RVMD Healthcare Biotechnology
Revolution Medicines, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $11.6 million, down 67.3% from fiscal 2022.
- Revenue
- +1,188.7%
- EPS
- −18.0%
- Free cash flow
- −99.1%
- Total debt
- +322.7%
Quarter to September 2026, against a year earlier
Follow RVMD
Alert me
Revolution Medicines, Inc. (RVMD) Operating cash flow
Revolution Medicines, Inc.'s operating cash flow for fiscal 2025 was −$897.7M, compared with −$557.4M in fiscal 2024. Over the twelve months to 30 September 2026 it was −$1.4B. Over the past ten years it has ranged from −$897.7M (fiscal 2025) to $1.2M (fiscal 2018) — the current reading is the lowest in ten years. Operating cash flow has fallen for 7 consecutive fiscal years. Revolution Medicines, Inc. ranks 603rd of 603 Biotechnology companies by operating cash flow.
Operating cash flow, annual
Embed this chart
Annual newest first
| Period | Operating cash flow | Change |
|---|---|---|
| FY2025 | −$897.7M | — |
| FY2024 | −$557.4M | — |
| FY2023 | −$350.6M | — |
| FY2022 | −$224.4M | — |
| FY2021 | −$147.2M | — |
| FY2020 | −$100.1M | — |
| FY2019 | −$49.6M | — |
| FY2018 | $1.2M | — |
| FY2017 | −$25.1M | — |
Quarterly newest first
| Period | Operating cash flow | Change |
|---|---|---|
| Sep 2026 | −$415.7M | — |
| Jun 2026 | −$387.3M | — |
| Mar 2026 | −$354.2M | — |
| Dec 2025 | −$274.2M | — |
| 29 more quarters | Free account |
Against its own ten years
Operating cash flow against peers
| Company | Operating cash flow |
|---|---|
| RPRX Royalty Pharma PLC compare | $3.0B |
| ARGX argenex SE compare | $1.6B |
| ONC BeOne Medicines Ltd. - Sponsored ADR compare | $1.6B |
| GMAB Genmab A/S Sponsored ADR compare | $891.0M |
| INCY Incyte Corporation compare | $745.0M |
| BNTX BioNTech SE Sponsored ADR compare | −$277.2M |
| INSM Insmed, Inc. compare | −$595.6M |
| ROIV Roivant Sciences Ltd. compare | −$816.5M |
| RVMD Revolution Medicines, Inc. | −$1.4B |
What Operating cash flow is
Operating Cash Flow shows how much cash a company’s day-to-day business actually brings in, after paying suppliers, staff and taxes.
Reported line item
More on RVMD
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement